U.S. Bio and Healthcare Stocks Surge as AI and Semiconductor Gains Slow

After a strong run, AI and semiconductor stocks are taking a breather, while U.S. bio and healthcare stocks are emerging as the new market leaders. Exchange-traded funds (ETFs) focused on these sectors are gaining momentum as investors shift funds from large-cap tech stocks to biotech, particularly small-cap companies with innovative technologies.

The ARKG ETF, which invests in gene therapy and other advanced biotech innovations, saw a 24.8% return over the past three months and an 83.5% gain since the start of the year. Other leading healthcare ETFs, such as XLV and VHT, which include major pharmaceutical companies like Johnson & Johnson and Merck, have also shown strong performance. The iShares Biotechnology ETF (IBB) posted nearly a 10% return in the last three months, driven by investor optimism in the sector.

Key factors fueling this surge include positive clinical trial results, increased M&A activity, and the integration of AI in biotech research. For example, Moderna and Merck's mRNA-based cancer vaccine, Intismeran Autogen, met key evaluation indicators in phase 3 trials, boosting their stock prices. Additionally, Amgen's positive phase 3 trial results for a new autoimmune disease treatment have further strengthened investor confidence. AI companies like Antropics are also expanding into biotech, using AI to analyze DNA data and discover new drug candidates.

However, the domestic bio industry in South Korea is struggling, with ETFs like KoAct BioHealthcare Active and KODEX Bio experiencing declines due to weak investor sentiment and interest rate hikes in major countries.